Clinical data | |
---|---|
Trade names | Teslac |
Other names | 13-Hydroxy-3-oxo-13,17-secoandrosta-1,4-dien-17-oic acid δ-lactone; SQ-9538; Fludestrin; NSC-12173; NSC-23759 |
AHFS/Drugs.com | Consumer Drug Information |
Routes of administration | By mouth |
Drug class | Aromatase inhibitor; Antiestrogen |
ATC code |
|
Pharmacokinetic data | |
Protein binding | ~85% |
Metabolism | Liver |
Excretion | Urine |
Identifiers | |
| |
CAS Number | |
PubChem CID | |
IUPHAR/BPS | |
DrugBank | |
ChemSpider | |
UNII | |
KEGG | |
ChEBI | |
ChEMBL | |
CompTox Dashboard (EPA) | |
ECHA InfoCard | 100.012.304 |
Chemical and physical data | |
Formula | C19H24O3 |
Molar mass | 300.398 g·mol−1 |
3D model (JSmol) | |
| |
(what is this?) (verify) |
Testolactone (INN , USAN ) (brand name Teslac) is a non-selective, irreversible, steroidal aromatase inhibitor which is used as an antineoplastic drug to treat advanced-stage breast cancer.[1][2][3][4] The drug was discontinued in 2008 and is no longer available for medical use.[4][5]
LemkeWilliams2012
was invoked but never defined (see the help page).